This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility: South Africa's malaria elimination teams could soon have backup from millions of decoy mosquitoes specially bred at Africa's first mosquito factory. These insects are part of South Africa's pioneering Sterile Insect Technique (SIT), developed through a joint partnership between the National Institute for Communicable Diseases (NICD) and Wits University.
NICD scientists have worked for a decade to rear and sterilize male swarms of Anopheles arabiensis to overwhelm the wild population. The idea is to supplement the country's existing Indoor Residual Spraying (IRS) efforts, which have helped shrink malaria spread by a home-dwelling mosquito called Anopheles funestus. Progress toward complete malaria elimination has stalled, though, and Anopheles arabiensis may be the culprit.
The insect can bypass IRS and insecticide-treated nets because it bites and rests outdoors. The method that the NICD and Wits University have devised exploits the fact that wild Anopheles arabiensis females mate only once in their lifetime. If they mate with sterile decoys, the resulting eggs won't be viable, leading to population collapse.
To demonstrate that this high-tech package works in the real world, the program conducted a historic 12-week small-scale field trial in Mamfene, KwaZulu-Natal, the first release of an African malaria vector. Over the trial period, researchers released approximately 50,000 sterile male mosquitoes biweekly, during which the target mosquito population declined. Once the releases stopped, the wild population rebounded, indicating that the decline was directly driven by the sterile male decoys.
Though findings have not yet been published or peer-reviewed, these early successes in Mamfene are just the beginning, says Dr. Givemore Munhenga, lead scientist of South Africa's SIT program. Munhenga and his colleagues are now gearing up to collect information to satisfy regulators, including larger epidemiological trials, a local elimination trial on Grande Glorieuse Island and eventually cross-border capacity building in neighboring countries.
To pave the way for this high-tech future, Wits Health Consortium hosted a scoping workshop Aug. 24–28. The goal of the event was to identify gaps between contained laboratory trials and operational, real-world deployment across the African continent. Participants heard about innovations at the cutting edge of biological vector control.
Extract — continue reading at the source.
